Vanc Pharmaceuticals Inc. (Form: 6-K, Received: 11/18/2014 08:44:06)

OMB APPROVAL

OMB Number:

3235-0116

Expires:

May 31, 2017

Estimated average burden

hours per response. . . . . . . … 8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of: September 2014

Commission File Number: 000-51848

Vanc Pharmaceuticals Inc.

(Translation of Registrant’s name into English)

#615 – 800 West Pender Street Vancouver, B C V6C 2V6

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F þ Form 40-F o

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note : Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Note : Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

SEC 1815 (04-09)

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Safe Harbor Statement

This Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the registrant and its business. Forward-looking statements are statements that are not historical facts and may be identified by the use of forward-looking terminology, including the words “believes,” “expects,” “intends,” “may,” “will,” “should” or comparable terminology. Such forward-looking statements are based upon the current beliefs and expectations of the registrant’s management and are subject to risks and uncertainties which could cause actual results to differ materially from the forward-looking statements.

Forward-looking statements are not guarantees of future performance and actual results of operations, financial condition and liquidity, and developments in the industry may differ materially from those made in or suggested by the forward-looking statements contained in this Form 6-K. These forward-looking statements are subject to numerous risks, uncertainties and assumptions. The forward-looking statements in this Form 6-K speak only as of the date of this report and might not occur in light of these risks, uncertainties, and assumptions. The registrant undertakes no obligation and disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Exhibits

The following exhibits are included in this Form 6-K:

99.1

Security Holder Docs – Certificate of Name Change

99.2

News Release – OTC Name Change

99.3

Material Change Report – OTC Name Change

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	NUVA Pharmaceuticals Inc.

Date: November 17, 2014	By:	Jamie Lewin
		Jamie Lewin, Chief Financial Officer

Exhibit 99.1

[F991002.GIF]

Confirmation of Service

Form Filed:

Notice of Alteration

Date and Time of Filing:

July 28, 2014 01:37 PM Pacific Time

Alteration Effective Date:

The alteration is to take effect at the time that this application is

filed with the Registrar.

Name of Company:

VANC PHARMACEUTICALS INC.

Incorporation Number:

BC0607937

This package contains:

Certified Copy of the Notice of Articles

Certificate of Name Change

Check your documents carefully to ensure there are no errors or omissions. If errors or omissions are discovered, please contact the Corporate Registry for instructions on how to correct the errors or omissions.

Page: 1 of 1

[F991004.GIF]

[F991006.GIF]

Notice of Articles

BUSINESS CORPORATIONS ACT

[F991008.GIF]

NOTICE OF ARTICLES

Name of Company:

VANC PHARMACEUTICALS INC.

REGISTERED OFFICE INFORMATION

Mailing Address:

Delivery address:

SUITE 615

800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

REGISTERED OFFICE INFORMATION

Mailing Address:

Delivery address:

SUITE 615

800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

Page 2 of 2

DIRECTOR INFORMATION

Last Name, First Name, Middle Name:

LEWIN, JAMIE

Mailing Address:

Delivery Address:

SUITE 615 - 800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

Last Name, First Name, Middle Name:

BEUKMAN, EUGENE

Mailing Address:

Delivery Address:

SUITE 615 - 800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

Last Name, First Name, Middle Name:

PIROOZ, SINA

Mailing Address:

Delivery Address:

SUITE 615 - 800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

Last Name, First Name, Middle Name:

BIANCO, MICHAEL

Mailing Address:

Delivery Address:

SUITE 615 - 800 WEST PENDER STREET

VANCOUVER BC V6C 2V6

CANADA

AUTHORIZED SHARE STRUCTURE

No Maximum

Common Shares

Without Par Value

Without Special Rights or Restrictions attached

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

[F991010.GIF]

Number: BC0607937

CERTIFICATE OF

CHANGE OF NAME

BUSINESS CORPORATIONS ACT

I Hereby Certify that NUVA PHARMACEUTICALS INC. changed its name to VANC PHARMACEUTICALS INC. on July 28, 2014 at 01:37 PM Pacific Time.

[F991012.GIF]

Exhibit 99.2

[F992002.GIF]

September 16, 2014 – VANC PHARMACEUTICALS INC. (the “ Company ” or “ VANC ”) is pleased to announce that its name has been changed with the Finance Industry Regulatory Authority in the US from Nuva Pharmaceuticals Inc. to Vanc Pharmaceuticals Inc. The trading symbol remains the same and is NUVPF.

This symbol is effective with all quote providers servicing US exchanges.

On behalf of:

VANC Pharmaceuticals Inc.

Jamie Lewin,

Director and CFO jlewin@vancpharm.com

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Exhibit 99.3

Form 51-102F3

Material Change Report

Item 1

Name and Address of Company

VANC PHARMACEUTICALS INC.

615-800 West Pender Street Vancouver, BC

V6C 2V6 (the “ Company ”)

Item 2

Date of Material Change

September 15, 2014

Item 3

News Release

The news release was disseminated on September 15, 2014 by way of the facilities of Stockwatch and Market News. Copies were also filed on SEDAR with the British Columbia Securities Commission and the Alberta Securities Commission.

Item 4

Summary of Material Change

The Company announced that its name has been changed with the Finance Industry Regulatory Authority in the US from Nuva Pharmaceuticals Inc. to Vanc Pharmaceuticals Inc.

Item 5

Full Description of Material Change

5.1

Full Description of Material Change

The Company announced its name has been changed with the Finance Industry Regulatory Authority in the US from Nuva Pharmaceuticals Inc. to Vanc Pharmaceuticals Inc. The trading symbol remains the same and is NUVPF.

This symbol is effective with all quote providers servicing US exchanges.

5.2

Disclosure for Restructuring Transactions

Not applicable.

Item 6

Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7

Omitted Information

Not applicable.

Item 8

Executive Officer

Jamie Lewin, Chief Financial Officer

Business Telephone:

604.687-2038

Facsimile:

604.687-3141

Item 9

Date of Report

September 16, 2014